{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:33:11Z","timestamp":1794029591714,"version":"4.8.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bursa Uludag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The aim of this study is to assess the efficacy and safety of nintedanib (NTD) therapy in a real world population of patients with connective tissue diseases related interstitial lung disease (CTDs-ILD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Our multicenter retrospective study included patients with a CTD-ILD diagnosis who started NTD treatment due to the development of PPF during follow-up. The results of the percentage predicted forced vital capacity (%pFVC) and percentage predicted diffusion capacity (%pDLCO) of patients before NTD treatment and 6, 12 and 18\u00a0months after the start of NTD treatment were evaluated. In addition, the patients were divided into two groups, SSc-ILD and other CTDs-ILD, and compared in terms of the efficacy and safety of the NTD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In all patients (<jats:italic>n<\/jats:italic>\u2009=\u200966), %pFVC and %pDLCO values stabilised after 6, 12 and 18\u00a0months compared to baseline values. All patients received at least one immunosuppressive therapy in combination with NTD treatment. The most common side effect after NTD treatment was diarrhoea (<jats:italic>n<\/jats:italic>\u2009=\u200920, 30.3%). When we divided the patients into two groups, SSc-ILD (<jats:italic>n<\/jats:italic>\u2009=\u200935) and other CTDs-ILDs (<jats:italic>n\u2009<\/jats:italic>=\u200931), no significant difference was found between the groups in the change in %pFVC (<jats:italic>p<\/jats:italic> values\u2009=\u20090.498, 0.595 and 0.376, respectively) and in the change in %pDLCO (<jats:italic>p<\/jats:italic> values\u2009=\u20090.817, 0.185 and 0.399, respectively) at 6, 12 and 18\u00a0months follow-up. Again, there was no statistically significant difference between the two groups in terms of adverse events and safety data after NTD treatment (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In summary, the use of NTD in combination with immunosuppressive therapies was effective and safe in SSc-ILD patients as well as in other CTDs-ILD patients.\n<jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\" colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>This multicenter study provides real-world data on the use of nintedanib in patients with connective tissue disease-interstitial lung disease.<\/jats:italic>\u2022 <jats:italic>Nintedanib treatment is as effective and safe in patients with other connective tissue disease as in patients with systemic sclerosis.<\/jats:italic>\n                      <\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07323-0","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:48:09Z","timestamp":1738946889000},"page":"1187-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: A multicenter retrospective study"],"prefix":"10.1007","volume":"44","author":[{"given":"Salim","family":"M\u0131s\u0131rc\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Ya\u011f\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belk\u0131s Nihan","family":"Co\u015fkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Ba\u015f\u0131b\u00fcy\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Merih","family":"Birlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Sar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin Dolu","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman Serdar","family":"Koca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6zde","family":"Y\u0131ld\u0131r\u0131m \u00c7etin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Okyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Atilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ediz","family":"Dalk\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"7323_CR1","doi-asserted-by":"publisher","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, et al (2024) 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res 0:1\u201313. https:\/\/doi.org\/10.1002\/acr.25348","DOI":"10.1002\/acr.25348"},{"key":"7323_CR2","doi-asserted-by":"publisher","unstructured":"Joy GM, Arbiv OA, Wong CK et al (2023) Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev 32. https:\/\/doi.org\/10.1183\/16000617.0210-2022","DOI":"10.1183\/16000617.0210-2022"},{"key":"7323_CR3","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00296-023-05313-6","volume":"43","author":"GM Koduri","year":"2023","unstructured":"Koduri GM, Podlasek A, Pattapola S et al (2023) Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis. Rheumatol Int 43:1515\u20131523. https:\/\/doi.org\/10.1007\/s00296-023-05313-6","journal-title":"Rheumatol Int"},{"key":"7323_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00408-020-00383-w","volume":"198","author":"N Jeganathan","year":"2020","unstructured":"Jeganathan N, Sathananthan M (2020) Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 198:735\u2013759. https:\/\/doi.org\/10.1007\/s00408-020-00383-w","journal-title":"Lung"},{"key":"7323_CR5","doi-asserted-by":"publisher","unstructured":"Sebastiani M, Venerito V, Laurino E et al (2023) Fibrosing progressive interstitial lung disease in rheumatoid arthritis: a multicentre Italian study. J Clin Med 12. https:\/\/doi.org\/10.3390\/jcm12227041","DOI":"10.3390\/jcm12227041"},{"key":"7323_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-017-2016-2","volume":"18","author":"P Saunders","year":"2017","unstructured":"Saunders P, Tsipouri V, Keir GJ et al (2017) Rituximab versus cyclophosphamide for the treatment of connective tissue diseaseassociated interstitial lung disease (RECITAL): Study protocol for a randomised controlled trial. Trials 18:1\u201311. https:\/\/doi.org\/10.1186\/s13063-017-2016-2","journal-title":"Trials"},{"key":"7323_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","volume":"80","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Distler O, Ryerson CJ et al (2021) Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 80:143\u2013150. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217230","journal-title":"Ann Rheum Dis"},{"key":"7323_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0961203314554849","volume":"24","author":"T Kurita","year":"2015","unstructured":"Kurita T, Yasuda S, Amengual O, Atsumi T (2015) The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis\/dermatomyositis. Lupus 24:3\u20139. https:\/\/doi.org\/10.1177\/0961203314554849","journal-title":"Lupus"},{"key":"7323_CR9","doi-asserted-by":"publisher","unstructured":"Johnson SR, Bernstein EJ, Bolster MB et al (2024) 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res 0:1\u201319. https:\/\/doi.org\/10.1002\/acr.25348","DOI":"10.1002\/acr.25348"},{"key":"7323_CR10","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A et al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45:1434\u20131445. https:\/\/doi.org\/10.1183\/09031936.00174914","journal-title":"Eur Respir J"},{"key":"7323_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/nejmoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071\u20132082. https:\/\/doi.org\/10.1056\/nejmoa1402584","journal-title":"N Engl J Med"},{"key":"7323_CR12","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/nejmoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381:1718\u20131727. https:\/\/doi.org\/10.1056\/nejmoa1908681","journal-title":"N Engl J Med"},{"key":"7323_CR13","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/nejmoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380:2518\u20132528. https:\/\/doi.org\/10.1056\/nejmoa1903076","journal-title":"N Engl J Med"},{"key":"7323_CR14","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205:E18\u2013E47. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"key":"7323_CR15","doi-asserted-by":"publisher","unstructured":"Boutel M, Boutou A, Pitsiou G et al (2023) Efficacy and safety of nintedanib in patients with connective tissue disease-interstitial lung disease (CTD-ILD): a real-world single center experience. Diagnostics 13. https:\/\/doi.org\/10.3390\/diagnostics13071221","DOI":"10.3390\/diagnostics13071221"},{"key":"7323_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002850","volume":"9","author":"C Campochiaro","year":"2023","unstructured":"Campochiaro C, De Luca G, Lazzaroni MG et al (2023) Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. RMD Open 9:e002850. https:\/\/doi.org\/10.1136\/rmdopen-2022-002850","journal-title":"RMD Open"},{"key":"7323_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152312","volume":"64","author":"PA Juge","year":"2024","unstructured":"Juge PA, Hayashi K, McDermott GC et al (2024) Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease. Semin Arthritis Rheum 64:152312. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152312","journal-title":"Semin Arthritis Rheum"},{"key":"7323_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-024-00400-y","volume":"8","author":"Y Ushio","year":"2024","unstructured":"Ushio Y, Wakiya R, Kameda T et al (2024) Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study. BMC Rheumatol 8:1\u20139. https:\/\/doi.org\/10.1186\/s41927-024-00400-y","journal-title":"BMC Rheumatol"},{"key":"7323_CR19","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s10787-023-01286-x","volume":"31","author":"M Di Battista","year":"2023","unstructured":"Di Battista M, Tavanti L, Pistelli F et al (2023) Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects. Inflammopharmacology 31:2445\u20132449. https:\/\/doi.org\/10.1007\/s10787-023-01286-x","journal-title":"Inflammopharmacology"},{"key":"7323_CR20","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815. https:\/\/doi.org\/10.1136\/ard.2009.114264","journal-title":"Ann Rheum Dis"},{"key":"7323_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2022.102245","volume":"65","author":"TM Wilson","year":"2022","unstructured":"Wilson TM, Solomon JJ, Demoruelle MK (2022) Treatment approach to connective tissue disease-associated interstitial lung disease. Curr Opin Pharmacol 65:1\u201310. https:\/\/doi.org\/10.1016\/j.coph.2022.102245","journal-title":"Curr Opin Pharmacol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07323-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:20:43Z","timestamp":1740558043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07323-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7323"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07323-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}